Literature DB >> 15902562

Evaluation of three biochemical markers in the monitoring of Gaucher disease.

A Vellodi1, Y Foo, T J Cole.   

Abstract

Several markers have been developed for the biochemical monitoring of Gaucher disease. Three of the most commonly used markers are acid phosphatase, angiotensin-converting enzyme (ACE) and chitotriosidase. The rationale for using all three concurrently is not clear. A retrospective study was therefore carried out on data collected from 28 paediatric patients treated with enzyme replacement therapy. All three markers fell with time. However, chitotriosidase showed the steepest time trend, the largest trend by case interaction, and the lowest residual variance, making it the most reliable of the three. ACE correlated strongly with chitotriosidase, but acid phosphatase did not correlate well with either and also had the largest residual variance, indicating that it was too 'noisy' to be informative. The absence of a 'gold standard' for assessing Gaucher disease complicates the interpretation of these findings, but they suggest that acid phosphatase be dropped from routine clinical practice, and that chitriosidase be used in preference to ACE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902562     DOI: 10.1007/s10545-005-0585-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  13 in total

1.  Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.

Authors:  Melissa P Wasserstein; Simon A Jones; Handrean Soran; George A Diaz; Natalie Lippa; Beth L Thurberg; Kerry Culm-Merdek; Elias Shamiyeh; Haig Inguilizian; Gerald F Cox; Ana Cristina Puga
Journal:  Mol Genet Metab       Date:  2015-05-30       Impact factor: 4.797

2.  Biochemical and Molecular Chitotriosidase Profiles in Patients with Gaucher Disease Type 1 in Minas Gerais, Brazil: New Mutation in CHIT1 Gene.

Authors:  Talita E R Adelino; Gustavo G Martins; Aretta A A Gomes; Adriana A Torres; Daniel A S Silva; Vinícius D O Xavier; João Paulo O Guimarães; Sérgio S S Araújo; Rachel A F Fernandes; Maria Christina L A Oliveira; Ana Lúcia B Godard; Eugênia R Valadares
Journal:  JIMD Rep       Date:  2012-10-13

3.  Role of chitotriosidase (chitinase 1) under normal and disease conditions.

Authors:  Manasa Kanneganti; Alan Kamba; Emiko Mizoguchi
Journal:  J Epithel Biol Pharmacol       Date:  2012

4.  ACE phenotyping in Gaucher disease.

Authors:  Sergei M Danilov; Victoria E Tikhomirova; Roman Metzger; Irina A Naperova; Tatiana M Bukina; Ozlem Goker-Alpan; Nahid Tayebi; Nurshat M Gayfullin; David E Schwartz; Larisa M Samokhodskaya; Olga A Kost; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2018-02-17       Impact factor: 4.797

5.  Spectrum of Lysosomal Storage Disorders at Tertiary Centre: Retrospective Case-Record Analysis.

Authors:  Ankur Singh; Rajniti Prasad; Om Prakash Mishra
Journal:  J Pediatr Genet       Date:  2020-01-02

6.  Substrate reduction therapy of glycosphingolipid storage disorders.

Authors:  Johannes M F G Aerts; Carla E M Hollak; Rolf G Boot; Johanna E M Groener; Mario Maas
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

7.  Bone events and evolution of biologic markers in Gaucher disease before and during treatment.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Corine Vincent; Olivier Fain; Bruno Fantin; France Mentré
Journal:  Arthritis Res Ther       Date:  2010-08-09       Impact factor: 5.156

8.  Chitotriosidase plasma activity in nephropathic cystinosis.

Authors:  A Xaidara; E M Karavitakis; K Kosma; F Emma; E Dimitriou; H Michelakakis
Journal:  J Inherit Metab Dis       Date:  2009-05-20       Impact factor: 4.982

Review 9.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

10.  Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.

Authors:  P Grigorescu Sido; C Drugan; V Cret; C Al-Kzouz; C Denes; C Coldea; A Zimmermann
Journal:  J Inherit Metab Dis       Date:  2007-08-20       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.